These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 33692175)

  • 1. Use of preclinical models for malignant pleural mesothelioma.
    Shamseddin M; Obacz J; Garnett MJ; Rintoul RC; Francies HE; Marciniak SJ
    Thorax; 2021 Nov; 76(11):1154-1162. PubMed ID: 33692175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-asbestos-related malignant pleural mesothelioma.
    Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
    Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
    Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
    J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
    Lin RT; Chang YY; Wang JD; Lee LJ
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic features of erionite-induced malignant mesothelioma.
    Demirer E; Ghattas CF; Radwan MO; Elamin EM
    Yonsei Med J; 2015 Mar; 56(2):311-23. PubMed ID: 25683976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia-Pacific Region.
    Ke H; Kao S; Lee K; Takahashi K; Goh HP; Linton A
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):177-190. PubMed ID: 34161674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
    Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
    Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Asbestos Fiber Burden Is Related to Patient Survival in Malignant Pleural Mesothelioma.
    Laaksonen S; Kettunen E; Sutinen E; Ilonen I; Vehmas T; Törmäkangas T; Räsänen J; Wolff H; Myllärniemi M
    J Thorac Oncol; 2022 Aug; 17(8):1032-1041. PubMed ID: 35367351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.
    Digifico E; Erreni M; Mannarino L; Marchini S; Ummarino A; Anfray C; Bertola L; Recordati C; Pistillo D; Roncalli M; Bossi P; Zucali PA; D'Incalci M; Belgiovine C; Allavena P
    Front Immunol; 2023; 14():1116430. PubMed ID: 37398648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATG5 as biomarker for early detection of malignant mesothelioma.
    Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L
    BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
    Kishimoto T; Fujimoto N; Ebara T; Omori T; Oguri T; Niimi A; Yokoyama T; Kato M; Usami I; Nishio M; Yoshikawa K; Tokuyama T; Tamura M; Yokoyama Y; Tsuboi K; Matsuo Y; Xu J; Takahashi S; Abdelgied M; Alexander WT; Alexander DB; Tsuda H
    BMC Cancer; 2019 Dec; 19(1):1204. PubMed ID: 31823764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-7 is expressed in malignant mesothelioma and has a prognostic value.
    Mai HL; Deshayes S; Nguyen TV; Dehame V; Chéné AL; Brouard S; Blanquart C
    Mol Oncol; 2022 Oct; 16(20):3606-3619. PubMed ID: 36054746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAM10 mediates malignant pleural mesothelioma invasiveness.
    Sépult C; Bellefroid M; Rocks N; Donati K; Gérard C; Gilles C; Ludwig A; Duysinx B; Noël A; Cataldo D
    Oncogene; 2019 May; 38(18):3521-3534. PubMed ID: 30651596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
    BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
    Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
    Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS signaling in malignant pleural mesothelioma.
    Marazioti A; Krontira AC; Behrend SJ; Giotopoulou GA; Ntaliarda G; Blanquart C; Bayram H; Iliopoulou M; Vreka M; Trassl L; Pepe MAA; Hackl CM; Klotz LV; Weiss SAI; Koch I; Lindner M; Hatz RA; Behr J; Wagner DE; Papadaki H; Antimisiaris SG; Jean D; Deshayes S; Grégoire M; Kayalar Ö; Mortazavi D; Dilege Ş; Tanju S; Erus S; Yavuz Ö; Bulutay P; Fırat P; Psallidas I; Spella M; Giopanou I; Lilis I; Lamort AS; Stathopoulos GT
    EMBO Mol Med; 2022 Feb; 14(2):e13631. PubMed ID: 34898002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.